Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer: A Retrospective Cohort Study. Issue 6 (July 2021)

• Record Type: Journal Article
• Authors: Han, Shilong; Cao, Chuanwu; Yuan, Yifeng; Chen, Jun; Yin, Linan; Xu, Huirong; Liu, Jingzhou; Wang, Wujie; Li, Yuliang; Wang, Lizhou; Zhou, Shi; Li, Fenqiang; Wang, Wenhui; Ji, Jiansong; Long, Haideng; Yin, Shiwu; Li, Jue; Han, Jianjun; Liu, Ruibao; Li, Maoquan; Zhang, Xiaoping
• Is Part Of: Pancreas. Volume 50:Issue 6(2021)
• Publication Date: 2021-07
• Subjects: advanced body/tail pancreatic cancer -- transcatheter arterial infusion -- radioactive particles; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001851
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: This retrospective cohort study investigated the efficacy of routine intravenous chemotherapy (the control group), transcatheter arterial infusion (TAI) chemotherapy, and TAI combined with radioactive particles as therapeutic methods for advanced body/tail pancreatic cancer by assessing the short-term and overall survival rates. Methods: We screened our prospective database for patients with advanced body/tail pancreatic cancer, which tumor deemed unresectable, and no other confirmed malignant tumors, patients were assigned into 3 groups according to their treatment: routine intravenous chemotherapy, TAI, and TAI combined with radioactive particles. Results: The median survival time was 6 months in the control group, 10 months in the TAI group, and 13 months in the TAI combined group. The Kaplan-Meier estimates of the overall survival among the 3 groups, indicating that there is significant difference among 3 groups ( P < 0.000). The clinical remission rates were 17.5% in the control group, 41.5% in the TAI group, and 48.0% in the TAI combined group. Covariates analyzed showed that different treatment methods and times affected the results significantly ( P < 0.002). Conclusions: In the treatment of advanced body/tail pancreatic cancer, TAI and TAI combined with radioactive particles significantly improved the clinical outcomes in patients compared with routine intravenous chemotherapy.